Profiel
Micah Zajic worked as a Senior Director of Corporate Strategy at Alexion Pharmaceuticals, Inc. from 2014 to 2017.
He then served as the Vice President of Corporate Development at MeiraGTx Ltd.
from 2017 to 2020.
In 2020, he joined SQZ Biotechnologies Co. as the Chief Financial Officer for a year.
In 2023, he briefly worked as the Chief Business Officer at Lexeo Therapeutics, Inc. Mr. Zajic completed his undergraduate degree at Georgetown University.
Eerdere bekende functies van Micah Zajic
| Bedrijven | Functie | Einde |
|---|---|---|
| LEXEO THERAPEUTICS, INC. | Financieel Directeur/CFO | 01-07-2023 |
| SQZ BIOTECHNOLOGIES COMPANY | Financieel Directeur/CFO | 31-12-2022 |
MeiraGTx Ltd.
 MeiraGTx Ltd. Pharmaceuticals: MajorHealth Technology MeiraGTx Ltd. engages in the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company was founded on March 20, 1991 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 01-09-2020 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-04-2017 |
Opleiding van Micah Zajic
| Georgetown University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| SQZ BIOTECHNOLOGIES COMPANY | Health Technology |
| LEXEO THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
MeiraGTx Ltd.
MeiraGTx Ltd. Pharmaceuticals: MajorHealth Technology MeiraGTx Ltd. engages in the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company was founded on March 20, 1991 and is headquartered in London, the United Kingdom. | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
